Gilead Sciences Inc.

26 de jun. de 2026, 22:11 UTC

Gilead Sciences Inc shares are lower in after-market hours, driven by notable declines in the Biotechnology sub-sector. No specific company news was identified.

25 de jun. de 2026, 23:56 UTC

Gilead Sciences shares moved higher in after-market hours, despite earlier declines during regular trading amid mixed U.S. market performance influenced by economic data.

24 de jun. de 2026, 23:36 UTC

Gilead Sciences' Trodelvy receives FDA approval for first-line treatment of triple-negative breast cancer, boosting shares in after-market hours.

23 de jun. de 2026, 23:56 UTC

European Commission approves Gilead's Trodelvy for triple-negative breast cancer, boosting shares higher in after-market hours amid notable intraday fluctuations.

22 de jun. de 2026, 23:02 UTC

Gilead Sciences Inc shares are lower in after-market hours, reversing earlier gains and settling near the lower end of their one-month trading range.

18 de jun. de 2026, 23:06 UTC

Gilead Sciences shares are lower in after-market trading, reflecting a decline since Thursday's close and nearing the lower end of their one-month range.

17 de jun. de 2026, 23:16 UTC

Gilead Sciences Inc. shares are lower in after-market hours, with notable volatility earlier in the session. No specific news was identified to explain the decline.

16 de jun. de 2026, 23:36 UTC

Gilead Sciences Inc. shares gained slightly in after-market trading, fluctuating within a narrow range amid limited volatility and no specific company news.

15 de jun. de 2026, 21:11 UTC

Gilead Sciences' supplemental New Drug Application for Yeztugo accepted by the FDA. Shares are lower in after-market trading despite the regulatory milestone.

12 de jun. de 2026, 23:01 UTC

Gilead Sciences Inc. shares are higher in after-market trading, gaining slightly since Friday's close despite mixed broader market sentiment.

11 de jun. de 2026, 23:02 UTC

Gilead Sciences reported positive results from two Phase 3 trials for an HIV treatment. Shares are higher in after-market hours following a session pullback.

10 de jun. de 2026, 23:11 UTC

Gilead Sciences shares rose in after-market trading, driven by a strong Biotechnology sub-sector trend. The stock remains below its 20-day moving average.

9 de jun. de 2026, 23:21 UTC

Gilead Sciences Inc shares are higher in after-market trading, rebounding from earlier losses despite remaining below the 20-day moving average.

8 de jun. de 2026, 23:26 UTC

Gilead Sciences Inc. shares declined in after-market trading following the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study for Trodelvy and Keytruda.

5 de jun. de 2026, 23:46 UTC

Gilead Sciences shares declined in after-market trading amid broader market pressures from strong U.S. job growth raising interest rate concerns.

4 de jun. de 2026, 19:46 UTC

Gilead Sciences is gaining amid social media discussions on its strategic positioning and attention at Goldman Sachs' healthcare conference.

3 de jun. de 2026, 23:01 UTC

Gilead Sciences Inc. is higher in after-market trading, driven by gains in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

2 de jun. de 2026, 23:02 UTC

Gilead Sciences reported positive Phase 3 study results for Livdelzi® in treating primary biliary cholangitis. Shares are trading higher in after-market hours.

1 de jun. de 2026, 20:03 UTC

Gilead Sciences Inc. shares are lower amid broader market concerns, despite plans to present over 25 abstracts at the ASCO Annual Meeting and EHA Congress.

29 de mai. de 2026, 20:02 UTC

Gilead Sciences is declining during Friday's session, despite the World Health Organization considering it for Ebola therapies. Shares rebounded earlier but fell back.

28 de mai. de 2026, 23:02 UTC

Gilead Sciences Inc shares are lower in after-market hours, reflecting broader market weakness amid disappointing jobless claims and inflation data.

27 de mai. de 2026, 23:02 UTC

Gilead Sciences shares are higher in after-market hours, recovering from earlier losses. The move comes amid broader market concerns about inflation and monetary policy.

26 de mai. de 2026, 20:02 UTC

Gilead Sciences shares are lower today despite a positive EMA opinion for Trodelvy® as a treatment for triple-negative breast cancer.

22 de mai. de 2026, 20:02 UTC

Gilead Sciences shares rise following FDA's accelerated approval of Hepcludex for chronic hepatitis delta virus, addressing a critical medical need.

21 de mai. de 2026, 20:06 UTC

Gilead Sciences renewed a five-year partnership with WHO to combat visceral leishmaniasis and acquired Tubulis GmbH for $3.15 billion. Shares are trading roughly flat.

20 de mai. de 2026, 23:46 UTC

Gilead Sciences has issued $3 billion in senior notes for general corporate purposes. Shares are trading lower during after-market hours amid ongoing pressure.

19 de mai. de 2026, 23:01 UTC

Gilead Sciences Inc shares are lower in after-market trading, despite positive economic data. The stock is near the lower end of its one-month trading range.

18 de mai. de 2026, 23:56 UTC

Gilead Sciences shares are modestly higher in after-market trading, recovering from earlier dips despite being below the 20-day moving average.

15 de mai. de 2026, 22:21 UTC

Gilead Sciences shares are lower in after-market hours, continuing a trend of declining daily closes and remaining below the 20-day moving average.